Drugs & Targets Amgen acquires rights from Boehringer Ingelheim for BI 836908 (AMG 420) September 09, 2016Vol.42 No.33
Drugs & Targets Regeneron Pharmaceuticals and Adicet Bio to develop next-gen engineered immune cell therapeutics September 09, 2016Vol.42 No.33
Drugs & Targets Palmetto GBA issues final local coverage determination for ProMark September 09, 2016Vol.42 No.33
Drugs & Targets BTG International Canada receives approval from Health Canada for DC Bead LUMI September 09, 2016Vol.42 No.33
Drugs & Targets EMA accepts for review Mylan’s MAA for a proposed biosimilar trastuzumab September 09, 2016Vol.42 No.33
Drugs & Targets Cumberland Pharmaceuticals begins distributing Ethyol (amifostine) for injection September 09, 2016Vol.42 No.33
Drugs & Targets 21 Hospitals Around China Will Adopt Watson for Oncology September 09, 2016Vol.42 No.33
Drugs & Targets The Department of Pathology at the Icahn School of Medicine at Mount Sinai established the Center for Computational and Systems Pathology September 06, 2016Vol.42 No.32
Drugs & Targets Novartis and MEI Pharma Receive Breakthrough Therapy Designations September 06, 2016Vol.42 No.32
